BRAF and cancer: This loss is not however limited to MSI-high cancers, but is also found in microsatellite stable (MSS) tumors with BRAF mutation and high-level CpG island methylator phenotype (CIMP), in other words, in cancers deriving from the so-called serrated pathway [10].